Collegium Pharmaceutical Inc
NASDAQ:COLL
Collegium Pharmaceutical Inc
Collegium Pharmaceutical, Inc. operates as a pharmaceutical company. The company is headquartered in Stoughton, Massachusetts and currently employs 152 full-time employees. The company went IPO on 2015-05-07. Collegium is a diversified, specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. The firm's product portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR (Nucynta Products), which are extended-release (ER) and immediate-release (IR) formulations of tapentadol. Xtampza ER is formulated using its abuse-deterrent technology platform, DETERx. Xtampza ER is for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Nucynta ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic.
Collegium Pharmaceutical, Inc. operates as a pharmaceutical company. The company is headquartered in Stoughton, Massachusetts and currently employs 152 full-time employees. The company went IPO on 2015-05-07. Collegium is a diversified, specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. The firm's product portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR (Nucynta Products), which are extended-release (ER) and immediate-release (IR) formulations of tapentadol. Xtampza ER is formulated using its abuse-deterrent technology platform, DETERx. Xtampza ER is for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Nucynta ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic.
Record Results: Collegium delivered record Q3 revenue of $209.4 million, up 31% year-over-year, and record adjusted EBITDA of $133 million, up 27% year-over-year.
Jornay PM Growth: Jornay PM posted $41.8 million in net revenue, with prescriptions up 20% year-over-year and market share rising to 23.4%.
Pain Portfolio Strength: Pain portfolio revenue hit $167.6 million, up 11% year-over-year, with all three core pain medicines showing growth.
Raised Guidance: Management increased 2025 guidance, now expecting total product revenue of $775–785 million (up 24% year-over-year) and Jornay revenue of $145–150 million.
Improved Profitability: Operating cash flow reached $78.4 million, debt was reduced by $16.1 million, and net leverage dropped to 1.2x.
Sales Force Expansion: Sales force expansion for Jornay was largely completed before back-to-school season; most impact expected in 2026 and beyond.
Gross to Net Improvement: Gross to net for Jornay improved to 62% in Q3 from 67% in Q2, driven by seasonality, improved returns, and favorable contracting.
